硫酸ネオマイシン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競争別セグメント、2020-2030F

硫酸ネオマイシンの世界市場は、2024年に2億4,680万米ドルと評価され、2030年には3億8,205万米ドルに達し、CAGR 5.22%で成長すると予測されています。

広スペクトルアミノグリコシド系抗生物質である硫酸ネオマイシンは、ヒトおよび動物の細菌感染症の治療に広く使用されています。その有効性、手頃な価格、外用剤や経口剤への応用により、皮膚疾患や胃腸疾患などの感染症管理に好んで使用されています。特に清潔な水や衛生設備へのアクセスが限られている新興国市場では、細菌感染症が増加し、予防ヘルスケアへの関心が高まっていることから、市場は拡大しています。硫酸ネオマイシンの治療上の多様性と費用対効果の高さは、医薬品と獣医学の両方の領域でその使用を支え続けています。

市場促進要因

ヘルスケア産業の成長

主な市場課題

副作用

主要市場動向

獣医療分野における硫酸ネオマイシンの需要増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の硫酸ネオマイシン市場に与える影響

第5章 世界の硫酸ネオマイシン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 販売チャネル別（直接、間接）
  • 用途別（皮膚感染症、眼感染症、耳感染症、ワクチン製造、獣医学、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の硫酸ネオマイシン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の硫酸ネオマイシン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の硫酸ネオマイシン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の硫酸ネオマイシン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの硫酸ネオマイシン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 世界の硫酸ネオマイシン市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinyao Xinrui Pharmaceutical
• Xinyu Pharmaceutical
• Renfu Pharmaceutical

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Neomycin Sulphate Market was valued at USD 246.80 million in 2024 and is projected to reach USD 382.05 million by 2030, growing at a CAGR of 5.22%. Neomycin sulphate, a broad-spectrum aminoglycoside antibiotic, is widely used to treat bacterial infections in both humans and animals. Its effectiveness, affordability, and application in topical and oral formulations make it a preferred choice in managing infections such as skin conditions and gastrointestinal disorders. The market is expanding due to rising incidences of bacterial infections and increased focus on preventive healthcare, especially in developing regions where limited access to clean water and sanitation persists. Neomycin sulphate's therapeutic versatility, combined with its cost-effectiveness, continues to support its use across both pharmaceutical and veterinary domains.

Key Market Drivers

Growth in Healthcare Industry

The ongoing expansion of the global healthcare industry is significantly driving demand for neomycin sulphate. With global healthcare generating over USD 4 trillion annually, the pharmaceutical and biotechnology segments alone account for approximately USD 850 billion. Neomycin sulphate plays a critical role in treating infections of the skin, eyes, and intestines, and is frequently used in both over-the-counter and prescription drugs. The growing burden of infectious diseases, especially in developing economies with inadequate sanitation infrastructure, reinforces the need for effective antimicrobials. Healthcare institutions rely heavily on neomycin sulphate for its broad-spectrum antibacterial capabilities, particularly in outpatient and surgical environments. As healthcare access improves globally, so does the reliance on reliable antibiotics like neomycin sulphate to manage and prevent infection-related complications.

Key Market Challenges

Adverse Side Effects

A major challenge in the global neomycin sulphate market is the potential for severe side effects associated with its prolonged or high-dose use. While effective, the antibiotic can cause nephrotoxicity and ototoxicity, leading to kidney damage and hearing loss. These risks have led to increased caution among healthcare providers and stricter regulatory oversight. As a result, neomycin sulphate usage is often limited to short-term or topical applications in human medicine. Meanwhile, the veterinary sector faces heightened scrutiny due to the risk of antibiotic residues in animal-derived products, which raises public health concerns. This has led to a gradual shift toward alternative antibiotics with better safety profiles.

Key Market Trends

Rising Demand of Neomycin Sulphate in Veterinary Sectors

A growing trend in the neomycin sulphate market is its increasing use in veterinary medicine. Chickens dominate global poultry production, comprising over 90% of the sector, followed by ducks, turkeys, guineafowl, and geese. As global demand for animal protein rises, so does the need for effective veterinary antibiotics. Neomycin sulphate is widely used to treat gastrointestinal and topical bacterial infections in livestock and poultry due to its proven efficacy against gram-negative bacteria. This trend is particularly pronounced in regions with large-scale animal farming operations, where maintaining animal health is essential for productivity and food safety.

Key Market Players

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinyao Xinrui Pharmaceutical
• Xinyu Pharmaceutical
• Renfu Pharmaceutical

Report Scope:

In this report, the Global Neomycin Sulphate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neomycin Sulphate Market, By Sales Channel:

• Direct
• Indirect

Neomycin Sulphate Market, By End Use:

• Skin Infection
• Eye Infection
• Ear Infection
• Vaccine Production
• Veterinary Medicine
• Others

Neomycin Sulphate Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neomycin Sulphate Market.

Available Customizations:

Global Neomycin Sulphate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Neomycin Sulphate Market

5. Global Neomycin Sulphate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Neomycin Sulphate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neomycin Sulphate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Neomycin Sulphate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Neomycin Sulphate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Neomycin Sulphate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Neomycin Sulphate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Neomycin Sulphate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Neomycin Sulphate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Neomycin Sulphate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Neomycin Sulphate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Neomycin Sulphate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neomycin Sulphate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Neomycin Sulphate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Neomycin Sulphate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Neomycin Sulphate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Neomycin Sulphate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Neomycin Sulphate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neomycin Sulphate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Neomycin Sulphate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Neomycin Sulphate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Neomycin Sulphate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neomycin Sulphate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Neomycin Sulphate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Neomycin Sulphate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neomycin Sulphate Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Limited
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• 15.3. Myland Pharma Pvt Ltd
• 15.4. Xi'an International Healthcare Factory Co., Ltd.
• 15.5. Shandong Yifan Chemical Technology Co., Ltd.
• 15.6. Xi'an Henrikang Biotech Co., Ltd.
• 15.7. Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• 15.8. Jinyao Xinrui Pharmaceutical
• 15.9. Xinyu Pharmaceutical
• 15.10. Renfu Pharmaceutical

16. Strategic Recommendations

17. About Us & Disclaimer